PharmaShots | Incisive News in 3 Shots

Subscribe Now

Junshi

Junshi Signs an Exclusive License and Commercialization Agreement with Hikma for Toripalimab in Middle East and North Africa Region

Junshi Signs an Exclusive License and Commercialization Agreement with Hikma for Toripalimab in Middle East and North Africa Regio...

December 27, 2022

Junshi Reports MAA Submission of Toripalimab to the EMA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

Junshi Reports MAA Submission of Toripalimab to the EMA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

November 15, 2022

Junshi and Coherus Present Results of Toripalimab in P-III (JUPITER-02) Study as 1L Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at AACR 2022

Junshi and Coherus Present Results of Toripalimab in P-III (JUPITER-02) Study as 1L Treatment of Recurrent or Metastatic Nasophary...

April 11, 2022

Junshi Report First Patient Dosing in P-III Study of VV116 in Treatment of Moderate to Severe COVID-19 in China

Junshi Report First Patient Dosing in P-III Study of VV116 in Treatment of Moderate to Severe COVID-19 in China

March 16, 2022

Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab) Receive the NMPA’s Approval for the Treatment of RA & Two Other Indication

Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab) Receive the NMPA’s Approval for the Treatment of RA & Two Other...

March 8, 2022

Junshi Entered into a Collaboration with DotBio to Develop Cancer Therapies

Junshi Entered into a Collaboration with DotBio to Develop Cancer Therapies

January 6, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us